Cdc2-Like Kinase Inhibitor, TG003 (CAS 300801-52-9)
See product citations (6)
QUICK LINKS
Cdc2-Like Kinase Inhibitor, TG003 is a benzothiazole agent that acts as a specific and ATP-competitive inhibitor of Clk family members. Reports show that Cdc2-Like Kinase Inhibitor, TG003 modifies the regulation of alternative splicing modulated by phosphorylation of SR proteins in vitro, and rescues defects in the development of Xenopus caused by an overabundance of Clk activity. Additionally, it represses the dissociation of nuclear speckles and serine/arginine-rich protein phosphorylation. Cdc2-Like Kinase Inhibitor, TG003 has demonstrated no inhibiting affect on Clk3, protein kinase C, cAMP-dependent protein kinase, SRPK1, and SRPK2. Although TG009 is structurally analogous, it is may act to be 500-1000 times less potent on both Clk1/Sty and Clk4, and has been used as a negative control. Cdc2-Like Kinase Inhibitor, TG003 is an inhibitor of CLK1, CLK2 and CLK4.
Cdc2-Like Kinase Inhibitor, TG003 (CAS 300801-52-9) References
- Manipulation of alternative splicing by a newly developed inhibitor of Clks. | Muraki, M., et al. 2004. J Biol Chem. 279: 24246-54. PMID: 15010457
- Alternative splicing: a new drug target of the post-genome era. | Hagiwara, M. 2005. Biochim Biophys Acta. 1754: 324-31. PMID: 16260193
- Combination of Clk family kinase and SRp75 modulates alternative splicing of Adenovirus E1A. | Yomoda, J., et al. 2008. Genes Cells. 13: 233-44. PMID: 18298798
- Systems biology of coagulation initiation: kinetics of thrombin generation in resting and activated human blood. | Chatterjee, MS., et al. 2010. PLoS Comput Biol. 6: PMID: 20941387
- Zinc-induced modulation of SRSF6 activity alters Bim splicing to promote generation of the most potent apoptotic isoform BimS. | Hara, H., et al. 2013. FEBS J. 280: 3313-27. PMID: 23648111
- Modulation of p53β and p53γ expression by regulating the alternative splicing of TP53 gene modifies cellular response. | Marcel, V., et al. 2014. Cell Death Differ. 21: 1377-87. PMID: 24926616
- Development of an orally available inhibitor of CLK1 for skipping a mutated dystrophin exon in Duchenne muscular dystrophy. | Sako, Y., et al. 2017. Sci Rep. 7: 46126. PMID: 28555643
Ordering Information
| Product Name | Catalog # | UNIT | Price | Qty | FAVORITES | |
Cdc2-Like Kinase Inhibitor, TG003, 5 mg | sc-202528 | 5 mg | $139.00 | |||
Cdc2-Like Kinase Inhibitor, TG003, 25 mg | sc-202528A | 25 mg | $548.00 |